Read how NIAID scientists are progressing toward a faster, more practical way to screen people and animals for prion diseases.
Inventors Recognition Program
In the second half of FY 2014, NIAID recognized the following individuals for their contributions to the U.S. patents listed below (only current NIAID employees are shown):
United States patent US 8,568,739 was issued on Oct. 29, 2013, for Antigenic chimeric tick-borne encephalitis virus/dengue virus type 4 recombinant viruses. NIAID inventor: Alexander Pletnev, Ph.D., D.Sci.
United States patent US 8,632,782 was issued on Jan. 21, 2014, for Recombinant attenuated dengue viruses comprising mutations in NS5 and the 3' untranslated region. NIAID inventor: Stephen Whitehead, Ph.D.
United States patent US 8,637,310 was issued on Jan. 28, 2014, for Use of a rock inhibitor to sustain primary human keratinocytes in a proliferative state. NIAID inventor: Alison McBride, Ph.D.
United States patent US 8,715,686 was issued on May 6, 2014, for Conformationally stabilized HIV envelope immunogens. NIAID inventors: Peter Kwong, Ph.D.; John Mascola, M.D.
United States patent US 8,748,572 was issued on June 10, 2014, for RNase a peptides, fragments, and uses thereof. NIAID inventor: Helene Rosenberg, M.D., Ph.D.
United States patent US 8,772,238 was issued on July 8, 2014, for Use of ixolaris, a tissue factor inhibitor, for the treatment of cancer. NIAID inventor: Ivo Francischetti, M.D. Ph.D.; José Ribeiro, M.D., Ph.D.
United States patent US 8,791,074 was issued on July 29, 2014, for Mutated anthrax toxin protective antigen proteins that specifically target cells containing high amounts of cell-surface metalloproteinases or plasminogen activator receptors. NIAID inventor: Stephen Leppla, Ph.D.
Recent Collaborative Agreements
NIAID and Knopp Biosciences, LLC, signed a cooperative research and development agreement (CRADA) to study an open-label, proof-of-concept study to evaluate the safety and efficacy of Dexpramiexole, a Knopp BioSciences, LLC, proprietary drug, in subjects with hypereosinophilic syndrome. NIAID principal investigator: Amy Klion, M.D.
NIAID and MedImmune, LLC, signed a CRADA to study the safety and efficacy of Benralizumab, Medimmune, LLC's proprietary monoclonal antibody, for the treatment of treatment-refractory hypereosinophilic syndrome. NIAID principal investigator: Amy D. Klion, M.D.
NIAID and the University of North Carolina at Chapel Hill entered a research collaboration agreement (RCA) to analyze the progeny of genetic cross of Plasmodium vivax for the identification of genes responsible for chloroquine resistance. NIAID principal investigator: Thomas Wellems, M.D, Ph.D.
NIAID and Gilead Sciences, Inc., signed a CRADA to study the effect of collaborator's proprietary immunomodulators on immune cells from chronically infected hepatitis B subjects and identification of hepatitis B virus strains with high infectivity in cell culture. NIAID principal investigator: Shyamasundaran Kottilil, M.D., Ph.D.
NIAID, WellcomeTrust Sanger Institute, and University of Oxford (incl. Isis Innovation) entered into an RCA to analyze the genomes of the parents and progeny of a Plasmodium falciparum cross that differ in their responses to artemisinin and other anti-malarial drugs. NIAID principal investigator: Thomas Wellems, M.D, Ph.D.
NIAID and Institut Pasteur of Shanghai entered into an RCA to study the role of neuropeptide Y-mediated protection or immune response in host defense, tissue repair, and neuropathogenesis of encephalitis. NIAID principal investigator: Karin Peterson, Ph.D.
NIAID and Vivaldi Biosciences, Inc., signed a CRADA to study the preclinical evaluation of a pandemic H7N9 live, attenuated influenza vaccine containing hemagglutinin (H7) and neuraminidase 9 (N9) influenza virus genes expressed in Vivaldi Biosciences Incorporated attenuated influenza virus strain with a truncated influenza non-structural protein 1 (NS1). NIAID principal investigator: Kanta Subbarao, M.B.B.S., M.P.H.
NIAID and GE Healthcare entered into an RCA to use an imaging product developed at GE to image high-consequence pathogens in animal models. NIAID principal investigator: Peter Jahrling, Ph.D.
NIAID and Merck Sharp & Dohme Corp. entered into an RCA to identify biochemical and molecular effects of genetic mutations on cell function and identify potential targets for therapy. NIAID principal investigator: Michael Lenardo, M.D.
NIAID and EMD Serono Research Institute, Inc., signed a CRADA to explore the similarities between parasite and cancer-induced immune tolerance with EMD Serono, Inc., proprietary tumor cell lines for the identification of new immunomodulatory therapeutic concepts. NIAID principal investigator: Thomas B. Nutman, M.D.
NIAID and Piramal Enterprises Limited entered into an RCA to understand the biological mechanisms through which the interested compound exhibits its anti-mycobacterial potential and the adaptive responses offered by the bacterium to the compound. NIAID principal investigator: Clifton Barry III, Ph.D.
NIAID and GeoVax, Inc., signed a CRADA to develop new modified vaccinia ankara (MVA) vaccine vectors for HIV vaccines. NIAID principal investigator: Bernard Moss, M.D., Ph.D.
NIAID and Regeneron Pharmaceuticals, Inc., signed a CRADA to generate magnesium transporter 1(MAGT1)-deficient human cell lines and evaluation of Regeneron Pharmaceuticals' MAGT1 knockout mouse strains for preclinical immunological disease analyses. NIAID principal investigator: Michael Lenardo, M.D.
NIAID and Genocea Biosciences, Inc., entered into an RCA to identify Plasmodium falciparum antigens that elicit antigen-specific CD8+ T-cell responses after natural exposure or infection. NIAID principal investigator: Peter D. Crompton, M.D., M.P.H.
NIAID, National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK/NIH), National Institute on Aging (NIA/NIH), National Cancer Institute (NCI/NIH), and Janssen Research and Development, Inc., signed a CRADA to characterize the molecular pathways of T regulatory and B regulatory cell activation and functions and their induction by myeloid cells in infections, autoimmunity, and tumors using proprietary systems pharmacology and biomarker Janssen technology. NIAID principal investigator: Yasmine Belkaid, Ph.D.
NIAID and University of Kansas entered into an RCA to study the relative solubility of three equine encephalitis virus-like particles (EEVLPs) using a PEG-solubility assay. NIAID principal investigator: Richard Schwartz, Ph.D.
NIAID and Biogen Idec, Inc., signed a CRADA to evaluate Avonex (interferon beta-1a) in a nonhuman primate model of Ebola virus infection. NIAID principal investigator: Kathryn C. Zoon, Ph.D.
NIAID and DNA2.0 entered into an RCA to explore codon optimization algorithm(s) for protein expression in B. subtilis and B. anthracis. NIAID principal investigator: Stephen Leppla, Ph.D.
NIAID and Columbia University Medical Center (incl. Columbia Technology Ventures) entered into an RCA to identify optimized VRC01-class antibodies that are more potent at neutralizing HIV-1, have greater breadth of function, or show other improved product profiles for progression into technical development and clinical evaluation. NIAID principal investigator: John Mascola, M.D.
NIAID and BioValence signed a CRADA to assess the effectiveness of BioValence Sdn. Bdh.'s RetroMAD1 fusion protein against human immunodeficiency virus (HIV-1). NIAID principal investigator: Kim Hasenkrug, Ph.D.
NIAID and Infectious Disease Research Institute (IDRI) entered into an RCA to characterize stimulatory properties of recombinant proteins from NIAID’s sandfly salivary glands, proteins, and expression plasmids. NIAID principal investigator: Jesus Valenzuela, Ph.D.
NIAID and Crucell Vaccines Institute (part of Johnson & Johnson) signed a CRADA on Phase II studies of the safety and efficacy of Crucell Holland B.V.'s proprietary anti-influenza hemagglutinin monoclonal antibody CR6261 against H1N1 influenza infection in NIAID's influenza human challenge model. NIAID principal investigator: Jeffery K.Taubenberger, M.D., Ph.D.
Last Updated January 23, 2015